


PHARMACEUTICAL 2020



LIGAND PHARMACEUTICALS INC Rank 11 of 362





PHARMACEUTICAL 2020





LIGAND PHARMACEUTICALS INC Rank 11 of 362

The relative strengths and weaknesses of LIGAND PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIGAND PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 488% points. The greatest weakness of LIGAND PHARMACEUTICALS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 172% points.

The company's Economic Capital Ratio, given in the ranking table, is 306%, being 609% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,123,645
Cost of Goods Sold	0
Intangible Assets	305,677
Liabilities, Current	17,002
Liabilities, Non-Current	32,450
Other Assets	58,408
Other Compr. Net Income	808
Other Expenses	195,548
Other Liabilities	678,231
Other Net Income	802,360
Property and Equipment	7,185
Research and Development	55,908
Revenues	120,282
Selling, General and Administrative Expense	41,884

Output Variable	Value in 1000 USD
Assets	1,494,915
Liabilities	727,683
Expenses	293,340
Stockholders Equity	767,232
Net Income	629,302
Comprehensive Net Income	629,706
Economic Capital Ratio	306%